Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are among the major causes of death worldwide due to acute inflammation in the lung. AT-rich interactive domain-containing 5a (Arid5a) is an RNA-binding protein involved in inflammatory autoimmune disease through posttranscriptional control of Il6, Stat3 and Tbx21 gene expression. We found that Arid5a-deficient mice were highly refractory to bleomycin (BLM)-induced lethality. Arid5a deficiency suppressed lung pathology, cytokine production (especially, IL-6), and clinical symptoms in BLM-treated mice. Production of reactive oxygen species (ROS) in response to BLM-induced cellular damage was inhibited in Arid5a-deficient mice, potentially affecting the level of oxidized 1-palmitoyl-2-arachidonoyl-phosphaticylcholine (OxPAPC) production. OxPAPC, which is supposed to be a TLR4/ TLR2 ligand, stimulated expression of the Arid5a and Il6 genes. Thus, reduction of ROS production in Arid5a-deficient mice could mitigate OxPAPC production, which in turn decreases IL-6 production in vivo due to dysregulated post-transcriptional regulation by loss of Arid5a. Therefore, the control of Arid5a expression represents a potential therapeutic target for treatment of ALI and ARDS.
Introduction
Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are clinical conditions involving acute respiratory dysfunction associated with morbidity and mortality. These disorders are induced by multiple lung diseases, including interstitial pneumonia, chemical pneumonia or infectious diseases such as microbial and virus-initiated pneumonia (1, 2) . Mechanical ventilation is a useful technique for treatment of these diseases. However, therapies that specifically control ALI/ARDS have not been established.
Bleomycin (BLM)-induced lung injury is commonly used as a model of pulmonary fibrosis, and injection of BLM also causes ALI. BLM, a non-ribosomal peptide, is an antineoplastic antibiotic drug that forms a complex with oxygen and iron, leading to DNA strand breaks (3) . Such cellular damage induces the secretion of oxygen radicals and apoptosis. During the process of cell damage and apoptosis, a variety of cytotoxic factors such as reactive oxygen species (ROS), nitrogen species (NO) and inflammatory cytokines are also produced in the lung, and these molecules can directly damage cells via lipid and protein oxidization (4) . ROS, which are mainly generated from NADPH under oxidative stress, cause oxidization of host phospholipids, and some of the reaction products have biological activity. For example, oxidized 1-palmitoyl-2-arachidonoyl-phosphaticylcholine (OxPAPC) can stimulate TLR4/TLR2, thereby activating the TLR4-TRIF-TRAF6 axis via a MyD88-independent pathway (5, 6) . Consequently, OxPAPC regulated by ROS induces IL-6 production in macrophages, potentially resulting in a cytokine storm (6) .
IL-6, a multifunctional cytokine produced by a wide range of cell types, mediates vascular endothelial permeability and inflammation in the lung (7, 8) . Dysregulation of IL-6 is involved in the pathogenesis of a variety of respiratory disorders. In ARDS patients, the concentration of IL-6 in bronchoalveolar lavage fluid (BALF) can be more than 100-fold higher than that in healthy controls (9) . ALI and fibrosis are attenuated in Il6-deficient mice following BLM treatment (10) . Several genetic studies in both animals and humans have revealed an association between IL-6 and ALI, as well as airway remodeling in asthma. IL-6 is secreted by rat endothelial cells and macrophages after BLM treatment, but it remains unclear how the Il6 gene is up-regulated. In this study, we identified a novel mechanism, which controls Il6 gene expression in lung injury.
Recently, our group demonstrated that an RNA-binding protein, AT-rich interactive domain-containing 5a (Arid5a), controls the half-life of the Il6, Stat3 and Tbx21 mRNAs (11) (12) (13) . The ARID family of proteins, of which 15 members have been identified, contain the helix-turn-helix motif ARID domain and play important roles in development, tissue-specific gene expression and proliferation (14) . TLR4-inducible Arid5a binds to the IL-6 3′-untranslated region (UTR), which in turn prevents an RNase called Regnase-1 (Zc3h12a) from binding to the IL-6 3′UTR (11). Consequently, Arid5a deficiency decreases production of cytokines including IL-6 and IFN-γ in vivo, thereby inhibiting induction of experimental autoimmune encephalomyelitis and inflammation involved in sepsis (11, 13) .
In this study, we found that Arid5a contributes to severe lung inflammation after BLM injection through post-transcriptional control of Il6 gene expression, potentially leading to ALI and pulmonary fibrosis.
Methods

Ethics statement
Adult male C57BL/6 wild-type (WT) mice (6-8 weeks old) were obtained from CLEA, Japan, and Arid5a-deficient mice were prepared as previously described (11) (12) (13) . All animal experiments were performed in accordance with protocols approved by the Institutional Animal Care of WPI-IFReC, Osaka University. All surgeries were performed under anesthesia, and all reasonable efforts were made to minimize suffering.
Animal treatment protocol
WT and Arid5a-deficient mice were anesthetized with 2-methyl-2-butanol (250 mg kg −1 ; Sigma-Aldrich) by intraperitoneal injection, and a 1-cm midline cervical incision was made to expose the trachea. Intra-tracheal instillation of BLM (300 µg per mice; Nippon Kayaku, Tokyo, Japan) or vehicle (sterile isotonic saline solution), in a volume of 50 µl, was performed by using a microliter syringe (Terumo, Japan) with a bent needle. The cervical incision was immediately sutured shut after intra-tracheal instillation. The animals recovered quickly after surgery. 
Survival, histological and morphological assessment
After BLM treatment, mice were monitored to check survival. Seven days after BLM instillation, lungs were removed from WT and Arid5a-deficient mice and subjected to morphological study. In addition, the right lung of each animal was fixed in 4% of paraformaldehyde in PBS (Nacalai Tesque, Osaka, Japan) and subjected to tissue sectioning and staining. For morphological analysis, the tissues were cut into 5-µm sections and stained with H&E.
RNA isolation and real-time PCR
After BLM instillation, total mRNA was isolated from lung tissue by using Trizol reagent and purified by using the Qiagen RNeasy mini kit. cDNA was prepared from 300 ng of total RNA by using the Qiagen cDNA kit. Levels of Arid5a, collagen type 1 and IL-6 mRNAs were analyzed by real-time PCR (7900HT, Applied Biosystems).
BALF collection and cytokine measurements
Seven days after BLM treatment, mice were anesthetized, and a plastic cannula was inserted into the trachea. Next, a syringe was used to inject 1 ml of cold PBS into the lungs; after a few seconds, the PBS was withdrawn. BALF samples were centrifuged, and supernatants were used for cytokine measurement. ELISAs were used to determine the concentrations of cytokines (TNF-α, IL-6 and IFN-γ) in BALF. Lung tissues were washed and homogenized in protein lysis buffer containing anti-foam reagent. The resultant lung homogenates were centrifuged at 12 000 × g to remove insoluble debris. Lung tissue supernatant protein was equilibrated by using the Bio-Rad protein measurement kit, and then IL-6 levels were determined by means of ELISA (R&D Systems, Minneapolis, MN, USA).
Flow cytometry
Seven days after BLM treatment of WT and Arid5a-deficient mice, BALF and lung tissues were collected for cell counting. To collect BALF, the lung was rinsed 10 times with 1 ml cold PBS, and the resultant rinse fluid was centrifuged. Lung tissues were digested with 0.1% collagenase II and 2.4 U ml −1 dispase II (Sigma-Aldrich) in PBS. RBCs were lysed in lung tissue and BALF by using Ammonium-Chloride-Potassium (ACK) lysing buffer. The cells were suspended in cold PBS containing 3% fetal bovine serum and 0.02% NaN 3 and incubated with Fc Block antibodies (CD16/32), followed by staining of surface markers for lymphocytes, macrophages and neutrophils. The stained cells were analyzed by flow cytometry (FACSAria II, BD Biosciences).
Detection of ROS and OxPAPC production
After BLM treatment, BALF and lung tissue were collected from WT and Arid5a-deficient mice, and the cells were washed three times with cold PBS. RBCs were lysed by using ACK lysis buffer. Furthermore, ROS were measured by using DCFDA-cellular ROS detection assay kits (ab113851) following the kit protocol. A FACS Aria II was used to detect ROS production. OxPAPC was detected in BALF by using the E06 monoclonal antibody as described by Imai et al. (6) and western blots prepared from lung tissue homogenates.
Stimulation of murine alveolar macrophages with OxPAPC
Murine alveolar macrophage [MH-S (ATCC® CRL-2019™)] and OxPAPC (870604) were purchased from ATCC and Avanti Polar Lipids, respectively. OxPAPC was dissolved in BSA-containing RPMI medium. Macrophages were seeded in 6-or 24-well plates and stimulated with 50 µg ml −1 OxPAPC. Total mRNA and protein levels were measured by using real-time PCR, ELISA and western blotting.
Luciferase assay
In 24-well culture plates, TLR4-expressing HEK293 cells (5 × 10 5 cells per well) were seeded in 500 µl medium and kept overnight until they were 60-70% confluent. HEK293 cells were co-transfected with luciferase expression vectors of AP-1, NF-κB, IRF3, IL-6, TNF-α and Arid5a (100 ng per well) and Renilla luciferase vector (10 ng ml −1 as control) by using Lipofectamine 2000 (Invitrogen). After 24 h of transfection, cells were incubated with or without OxPAPC (50 µg ml −1 ) and LPS (100 ng ml −1 ) for an additional 24 h, and then Fig. 2 . Arid5a-deficient mice produce lower levels of IL-6 in response to BLM. WT and Arid5a-deficient mice were subjected to BLM-induced lung injury. Seven days after BLM injection, mice were euthanized, and lung tissue and BALF were collected in order to measure the levels of IL-6 in lung tissue (A) and BALF (B) by ELISA (n = 5, *P < 0.05; **P < 0.01).
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harvested. The luciferase activity in cell extracts was determined by using the Promega Dual Luciferase Assay Kit.
Statistical analysis
Statistical analysis was performed by using GraphPad Prism software. Differences between two groups were assessed by Student's t-test (two tailed) for statistically significant differences. Values of P <0.05 were regarded as statistically significant.
Results
Arid5a-deficient mice are less susceptible to BLM-induced lung injury
To determine a role of Arid5a in BLM-induced lung injury, we intra-tracheally administered a single dose of BLM (300 µg per mice) or PBS to WT and Arid5a-deficient mice. WT mice started to die within 8 days of treatment, and by the fourth week, 75% of the WT mice had died. By contrast, only 25% of Arid5a-deficient mice died (i.e. 75% survived) (Fig. 1A and Table 1 ). Seven days after BLM treatment, the lungs of WT became red, swollen and highly inflamed in comparison with those of Arid5a-deficient mice (Fig. 1B) . Histological studies of tissues stained with H&E revealed that Arid5a-deficient mice exhibited markedly less damage, hemorrhaging and cellular injury than WT mice (Fig. 1C) .
IL-6 expression in lung tissue and BAL fluid following BLM administration is significantly lower in
Arid5a-deficient mice
Seven days after BLM administration, lung tissue was removed, and then BLM-induced mRNA expression of Arid5a, type1-collagen and IL-6 mRNAs in lung tissue was measured. As a result, mRNA expression of IL-6 and type-1 collagen was lower in Arid5a-deficient than that in WT mice (Supplementary Figure 1A- C, available at International Immunology Online). In addition, we performed ELISA to measure IL-6, TNF-α and IFN-γ levels in BALF and/or lung tissue of WT and Arid5a-deficient mice. In Arid5a-deicient mice, the IL-6 level was dramatically reduced in both BALF and lung tissue ( Fig. 2A and B) , whereas TNF-α and IFN-γ were not detectable in BALF (data not shown). Next, we observed a significant increase in the number of immune cells including macrophages and neutrophils in BALF after BLM treatment; however, the number of cells seemed not to be different in between WT and Arid5a-deficient mice ( Supplementary  Figure 2A -D, available at International Immunology Online).
Production of ROS and oxidized phospholipids after BLM treatment
Previous studies have shown that after BLM injection, generated ROS production induces oxidative stress, mitochondrial leakage, apoptosis and ALI (15) . After BLM administration, the level of ROS production in BALF was lower in Arid5a-deficient mice than that in WT mice (Fig. 3A) . Because of the liquid-air interface, lung cells are exposed to an aerobic environment, promoting oxidation and formation of OxPAPC (6, 15) . In line with the previous report, reduction of ROS in BALF cells of Arid5a-deficient mice was associated with a decreased OxPAPC level in lung tissue of the mice (Fig. 3B) , whereas both levels of Arid5a mRNA and OxPAPC were elevated in the lung tissue after BLM (Fig. 3B and C) .
OxPAPC induces Arid5a and Il6 gene expression in murine alveolar macrophages
To determine whether OxPAPC induces the expression of the Arid5a and Il6 genes, we cultured murine alveolar macrophages, stimulated them with OxPAPC and monitored the expression of Arid5a, IL-6, TNF-α and Regnase-1 mRNAs. OxPAPC selectively induced the expression of Arid5a as well as IL-6 mRNA but not TNF-α and Regnase-1 ( Fig. 4A-D) .
OxPAPC-mediated AP1 activation is involved in the Il6 and Arid5a promoter activity
To determine the transcription factors involved in the production of cytokines, especially IL-6, after OxPAPC treatment, we transfected TLR4-expressing HEK293 cells with the luciferase reporters encoding the Ap1, Irf3, NF-κB, Il6, Tnfα, and Arid5a promoter regions ( Fig. 5A-F) . Luciferase activity was assessed after OxPAPC and LPS stimulation (as control). OxPAPC selectively induced the AP-1, Arid5a
and IL-6 promoter activity, indicating that AP-1 is one of the major transcription factors in this pathway. Furthermore, JNK inhibitor impaired the expression of Arid5a mRNA (Fig. 5G) . We also confirmed activation of the AP-1 transcription factor after OxPAPC treatment of alveolar macrophage (Fig. 5H) .
Discussion
Arid5a is an RNA-binding protein that stabilizes the mRNAs encoding the Il6, Stat3 and Tbx21 genes, thereby increasing IL-6 production in vivo (11) (12) (13) . We found that OxPAPC, a factor derived from damaged lung cells, induces Arid5a expression, possibly through TLR-4/TLR-2 signaling, following BLM-induced lung injury. Previous studies showed that OxPAPC generated by NADPH-mediated ROS in the lung can trigger overproduction of IL-6 after influenza infection (6, 14) . Notably, OxPAPC induces IL-6 (but not TNF-α) via the TLR4-TRAF6-TRIF axis during ALI associated with influenza infection (14) . Conceivably, OxPAPC generated during BLM-induced lung injury stimulates the expression of Arid5a, which in turn promotes IL-6 production, and thereby leading to further lung injury. Seven days after intra-tracheal injection of BLM, morphology and histology were grossly normal in Arid5a-deficient mice, in contrast to the situation in WT mice, and no inflammation or edema was observed. Moreover, the survival after BLM injection was significantly higher in Arid5a-deficient than WT mice. Considering the involvement of Arid5a in production of cytokines, especially IL-6, the pathogenic role of Arid5a in BLM-induced lung injury might occur at an early inflammatory stage. By contrast, because antibody blockade of IL-6 signaling at the early inflammatory stage exacerbates lung fibrosis (16) , Arid5a could play another important role in the pathogenesis at the early inflammatory stage, although further investigation will be needed.
During inflammation, the tissue recruits various types of immune cells, which increase production of cytokines and chemokines. Although we observed reduced levels of IL-6 mRNA and protein in Arid5a-deficient mice during BLM lung injury, the numbers of total lymphocytes, macrophages or neutrophils seemed not to be different. This result suggests that intrinsic roles of Arid5a protein in immune cells such as macrophages and T cells might significantly affect the phenotype of lung tissue because cytokine production, especially IL-6, was reduced in Arid5a-deficient mice. Although further investigation will be needed, the ratio of M1 and M2 macrophage cell populations might be altered as well as that of pro-or anti-inflammatory T cells. Considering the previous study involving Il6-deficient mice, Arid5a might also play an important role in the suppression of up-regulation of TGF-β1 and CCL3 during BLM-induced lung injury (10) .
Reduction of ROS production in Arid5a-deficient mice reveals one of the mechanisms by which lung inflammation is suppressed at the early inflammatory stage. BLM causes cell damage and apoptosis, potentially leading to the generation of superoxide (O 2 − ). Intracellular ROS are derived from superoxide, and mice with lower levels of ROS are protected from BLM-induced lung fibrosis (17) . BLM can also stimulate immune cells, which produce pro-inflammatory cytokines including IL-6 (18). Therefore, reduction of cytokine levels as a result of Arid5a deficiency might contribute to the decrease ROS generation. At present, however, it is difficult to specify the stage where Arid5a directly affects. Given that ROS modulate a wide variety of biological events, such as adaptation to hypoxia, autophagy, immunity and aging, it is necessary to determine how Arid5a controls ROS.
IL-6 production in BALF promotes lung fibrosis in BLMinduced lung injury, although its origin is not obvious. One possibility is that IL-6 is secreted in lung macrophages stimulated with irritants such as BLM, silica and asbestos. ROS generated in response to BLM can induce formation of OxPAPC, which stimulates IL-6 production in lung macrophages. Interestingly, OxPAPC promoted the expression of Arid5a and IL-6 mRNAs in a time-dependent manner, although OxPAPC did not stimulate expression of the Regnase-1 gene. Nevertheless, elevated levels of Arid5a protein could lead to augmentation of IL-6 level in BALF and lung tissue via the OxPAPC signaling pathway, as Arid5a positively controls the half-life of IL-6 mRNA. OxPAPC also selectively induces the activation of AP-1 transcription factor, which critically affect the expression of the Arid5a gene. Consequently, the augmentation of Arid5a expression via OxPAPC-mediated AP-1 activation might contribute to over-expression of IL-6 in vivo.
In summary, Arid5a contributes to the exacerbation of BLM-induced lung injury by controlling events at early inflammatory stage. Reduced ROS production in Arid5a-deficient mice contributes to the decreased level of OxPAPC from damaged cells, which could reduce the amount of IL-6 in BALF. Consequently, inhibition of Arid5a expression might be a useful therapeutic target for treatment of ALI and ARDS. 
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